NCT04665089View on ClinicalTrials.gov

Erythromycin in Septic Patients: Immunomodulatory Role and Clinical Impact

NACompletedINTERVENTIONAL

Enrollment

110

Participants

Timeline

Start Date

January 1, 2022

Primary Completion Date

January 30, 2023

Study Completion Date

April 30, 2023

Conditions

SepsisSeptic ShockImmunoinflammatory Response

Interventions

DRUG

Erythromycin

"Before each intervention (either at inclusion: day 0) and after the end of 5 days of erythromycin or placebo (day 6), the following dosages will be performed:~* Pro-inflammatory cytokine (TNF alpha)~* Anti-inflammatory cytokine (IL-10)~* Procalcitonin (PCT) Then, analysis of the variations in the TNF/ IL-10 ratio, the blood count, CRP and PCT parameters (between Day 0 and Day 6)"

Trial Locations (1)

1007

intensive care unit of the University Hospital Center La Rabta, Tunis

All Listed Sponsors

lead

Tunis University

OTHER

NCT04665089 - Erythromycin in Septic Patients: Immunomodulatory Role and Clinical Impact | Biotech Hunter | Biotech Hunter